Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial.

ABSTRACT:

Importance

Mavacamten has shown clinical benefits in global studies for patients with obstructive hypertrophic cardiomyopathy (oHCM), but evidence in the Asian population is lacking.

Objective

To evaluate the safety and efficacy of mavacamten compared with placebo for Chinese patients with symptomatic oHCM.

Design, setting, and participants

This phase 3, randomized, double-blind, placebo-controlled clinical trial was conducted at 12 hospitals in China. Between January 4 and August 5, 2022, patients with oHCM and a left ventricular outflow tract (LVOT) gradient of 50 mm Hg or more and New York Heart Association (NYHA) class II or III symptoms were enrolled and received treatment for 30 weeks.

Interventions

Patients were randomized 2:1 to receive mavacamten (star

SUBMITTER: Tian Z 

PROVIDER: S-EPMC10463173 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature